Prognostic value of FDG-PET/CT response for patient selection before chimeric antigen receptor-T-cells therapy in non-Hodgkin lymphoma

Clément Bailly^{1

2}, Thomas Carlier^{1

2}, Benoit Tessoulin^{1

3}, Thomas Gastinne³, Françoise Kraeber-Bodere^{1

2}, Steven Le Gouill^{1

3}, Caroline Bodet-Milin^{1

2}

Affiliations

Comment

Clément Bailly et al. Hematol Oncol. 2022 Oct.

. 2022 Oct;40(4):796-800.

doi: 10.1002/hon.2965. Epub 2022 Jan 23.

Clément Bailly^{1

2}, Thomas Carlier^{1

2}, Benoit Tessoulin^{1

3}, Thomas Gastinne³, Françoise Kraeber-Bodere^{1

2}, Steven Le Gouill^{1

3}, Caroline Bodet-Milin^{1

2}

No abstract available

Keywords: CAR T cells; FDG-PET/CT; MTV; R/R NHL.

Comment on

Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma.
Vercellino L, Di Blasi R, Kanoun S, Tessoulin B, Rossi C, D'Aveni-Piney M, Obéric L, Bodet-Milin C, Bories P, Olivier P, Lafon I, Berriolo-Riedinger A, Galli E, Bernard S, Rubio MT, Bossard C, Meignin V, Merlet P, Feugier P, Le Gouill S, Ysebaert L, Casasnovas O, Meignan M, Chevret S, Thieblemont C. Vercellino L, et al. Blood Adv. 2020 Nov 24;4(22):5607-5615. doi: 10.1182/bloodadvances.2020003001. Blood Adv. 2020. PMID: 33180899 Free PMC article.

1. Schuster SJ, Svoboda J, Chong EA, et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med. 2017;377(26):2545-2554. https://doi.org/10.1056/NEJMoa1708566
1. Johnson PC, Abramson JS. Patient selection for chimeric antigen receptor (CAR) T-cell therapy for aggressive B-cell non-Hodgkin lymphomas. Leuk Lymphoma. 2020;61(11):2561-2567. https://doi.org/10.1080/10428194.2020.1786563
1. Vercellino L, Di Blasi R, Kanoun S, et al. Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma. Blood Adv. 2020;4(22):5607-5615. https://doi.org/10.1182/bloodadvances.2020003001
1. Ruff A, Ballard HJ, Pantel AR, et al. 18F-Fluorodeoxyglucose positron emission tomography/computed tomography following chimeric antigen receptor T-cell therapy in large B-cell lymphoma. Mol Imag Biol. 2021;23(6):818-826. https://doi.org/10.1007/s11307-021-01627-8
1. Shah NN, Nagle SJ, Torigian DA, et al. Early positron emission tomography/computed tomography as a predictor of response after CTL019 chimeric antigen receptor -T-cell therapy in B-cell non-Hodgkin lymphomas. Cytotherapy. 2018;20(12):1415-1418. https://doi.org/10.1016/j.jcyt.2018.10.003